IPPRA / Grant Monitor

2026-07-07
← Board

Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)

PAR-25-184 · National Institutes of Health

mental behavioral health biomedical clinical ai data science Health

Closes
2027-10-15 · 465 d
Award ceiling
Award floor
Program funding
Expected awards
Cost sharing
No
Posted
2024-11-26
Instrument
Grant
Characterization · gpt-5.4-mini · 2026-07-07

NIH/NIMH funds early-stage experimental therapeutics studies of pharmacologic or neuromodulatory device interventions for mental disorders, including clinical testing plus mechanism-of-action work.

Funds
applied research
University
direct
social behavioral
substantial
physical sciences
minor
engineering
substantial
life biomedical
central
computational data
substantial

⚑ R61/R33 phased mechanism-testing clinical trial required · Experimental therapeutics approach required · Foreign organizations are eligible · Clinical trial pipeline NOFO; early-stage testing only

Unit fits — one characterization, each unit's own rules

Physical Sciences & Engineering (demo) 80 strong technical depth: substantial; funds applied research
IPPRA 58 good outside portfolio topics; social/behavioral work is substantial; funds applied research; biomedical core — IPPRA health lane is communication/crisis/policy (capped); clinical-trial/biomedical core — IPPRA angle is policy/community (capped)
Tom Love Innovation Hub 30 weak funds applied research; deep-tech content

Description

NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this NOFO encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this NOFO is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Apply

View on Grants.gov → CONTACT: National Institutes of Health <grantsinfo@nih.gov>

Proposal brief SEE AN EXAMPLE →

A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.

ONE LLM CALL (~1¢) · CACHED · REQUIRES STAFF KEY

Proposal shell · National Institutes of Health conventions SEE AN NIH EXAMPLE →

Funder-faithful document skeletons — National Institutes of Health's document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.

ONE LLM CALL (~2-3¢) · CACHED · SCAFFOLDING, NOT GHOSTWRITING